RNS Number : 8178E
Optos plc
01 October 2008
OPTOS PLC
("Optos" or the "Company" or the "Group")
Total Voting Rights and Issued Share Capital
LONDON - 01 October 2008: Optos plc (LSE: OPTS) confirms that, in accordance with the
provisions of the Financial Services Authority's
("FSA") Disclosure and Transparency Rules ("DTR" or the "Rules"), as at 30 September 2008, the
Company had an issued share capital of
69,527,475 Ordinary Shares of £0.02 per share which are admitted to trading and which carry
the right to one vote at general meetings of the
Company. The Company holds no shares in treasury. Therefore, the total number of voting rights
in the Company is 69,527,475. This figure may
be used by shareholders as the denominator for the calculations by which they will determine
whether they are required to notify their
interest in, or a change to their interest in, the Optos plc under the FSA's Disclosure and
Transparency Rules.
< ENDS >
Enquiries
Optos plc
Barbara Gubbins,
Company Secretarial Assistant
+44 (0)1383 843 359
Maitland
Brian Hudspith
+44 (0)20 7379 5151
About Optos plc
Optos plc is a leading medical retinal imaging technology company. Both eye and non-eye
diseases often first exhibit in the periphery of
the retina. These are very difficult to detect clinically with conventional examination
equipment and techniques. Optos' devices produce
ultra wide-field, high resolution images of approximately 82% of the retina, something no
other device is capable of doing in any one image.The images provide optometrists and ophthalmologists with enhanced clinical information which
facilitates the early detection, management
and treatment of disorders and diseases evidenced in the retina such as retinal detachments
and tears, glaucoma, diabetic retinopathy and
age-related macular degeneration. Retinal imaging can also indicate evidence of non-eye or
systemic diseases such as hypertension and
certain cancers. Optos has a range of medical devices that support different customer segments
and patient levels: P200 device is
concentrated on wellness screening carried out by optometrists and ophthalmologists in primary
care; P200C device is designed to meet the need for more exacting clinical imaging capabilities
and standards
in secondary care within the ophthalmology market and at optometric practices that are
clinically managing a patient base with advanced
ocular disease; P200MA device supports retinal specialists, working primarily with a diabetic
patient base, in the medical care market
through an advanced medical angiography procedure. Optos' technology provides an unequalled
combination of wide-field retinal imaging, speed
and convenience for the practitioner and patient resulting in more targeted treatment regimes
and improved patient outcomes. This can help
save sight and save lives. Optos estimates that it is addressing a market opportunity with a
combined $4 billion potential.
Forward-Looking Statements
Certain statements made in this announcement are forward-looking statements. These
forward-looking statements are not historical facts
but rather are based on the Company's current expectations, estimates and projections about
its industry, its beliefs and assumptions. Words
such as 'anticipates,' 'expects,' 'intends,' 'plans,' 'believes,' 'seeks,' 'estimates,' and
similar expressions are intended to identify
forward-looking statements. These statements are not guarantees of future performance and are
subject to known and unknown risks,
uncertainties and other factors, some of which are beyond the Company's control, are difficult
to predict and could cause actual results to
differ materially from those expressed or forecasted in the forward-looking statements. The
Company cautions shareholders and prospective
shareholders not to place undue reliance on these forward-looking statements, which reflect
the view of the Company only as of the date of
this announcement. The forward-looking statements made in this announcement relate only to
events as of the date on which the statements are made. The Company will not undertake any
obligation to
release publicly any revisions or updates to these forward-looking statements to reflect
events, circumstances or unanticipated events
occurring after the date of this announcement except as required by law or by any appropriate
regulatory authority.
This information is provided by RNS
The company news service from the London Stock Exchange
END
TVRUUGMWUUPRGUG
|